Cytogenetic profiles and their clinical significance in relapsed multiple myeloma
Multiple myeloma (MM) is a malignancy of monoclonal plasma cells. The overall survival varies from under two years to over ten years. The disease progresses from monoclonal gammopathy of undetermined clinical significance to smouldering multiple myeloma and eventually, MM. CCND1::IGH and/or trisomie...
Saved in:
Main Author: | Lin, Qian Yu |
---|---|
Other Authors: | - |
Format: | Final Year Project |
Language: | English |
Published: |
Nanyang Technological University
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/171641 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
by: Chng, W-J, et al.
Published: (2022) -
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
by: Moreau, Philippe, et al.
Published: (2021) -
Cytogenetic and molecular aberrations of multiple myeloma patients : a single-center study in Singapore
by: Ng, Yit Jun, et al.
Published: (2015) -
Clinical and biological significance of RAS mutations in multiple myeloma
by: Chng, W.J., et al.
Published: (2011) -
Clinical profiles of multiple myeloma in asia-an asian myeloma network study
by: Kim, K., et al.
Published: (2016)